ALZ-201 News - LARVOL Sigma

|||||||||| ALZ-201 / Alzinova
Journal: Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. (Pubmed Central) - Dec 29, 2022
Its unique specificity indicates that a low-abundant, soluble Aβ42 oligomer may account for much of the neurotoxicity in AD. This critical attribute identifies the potential of ALZ-201 as a novel drug candidate for achieving a true, clinical therapeutic effect in AD.

|||||||||| ALZ-201, A MONOCLONAL ANTIBODY THERAPY FOR SPECIFIC NEUTRALISATION OF TOXIC AMYLOID-Β IN ALZHEIMER’S DISEASE. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_201;
P1
We previously demonstrated that ALZ-201 specifically binds to a toxic species in post-mortem AD brain extracts to cause a positive physiological and protective impact on the integrity and morphology of mouse neurons. Biosimilars of aducanumab, lecanemab, and gantenerumab, on the other hand, were here shown to exhibit no conformational preference for Aβ, indicating that their weak binding to non-aggregated forms stem almost exclusively from fast binding off-rates.

|||||||||| ALZ-201 / Alzinova
[VIRTUAL] A novel specific Aβ 42 oligomer antibody ameliorates the neurotoxicity of patient-derived brain extracts () - Aug 2, 2021 - Abstract #AAIC2021AAIC_2892;
The unique antibody, ALZ-201, is capable of depleting these without targeting other forms of Aβ. Since this natural toxic form of Aβ is extremely low in abundance, this feature may be a critical attribute for achieving a true therapeutic effect in actual patients.



	Diseases Companies Products Productz Mechanisms of Action Sites